ArticleBMC health services research2026
Knowledge, attitudes and practices of health care professionals towards pharmacovigilance in Georgia.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPharmacovigilance (PV) is fundamental for public health, focusing on the detection, evaluation, and prevention of adverse drug reactions (ADRs). ADRs significantly contribute to global morbidity and mortality. Healthcare professionals (HCPs) play a crucial role in ensuring drug safety, as their expertise is essential for the timely identification, management, and reporting of ADRs. Despite the importance of PV, underreporting remains a critical challenge, particularly in developing countries. The PV system in Georgia is ineffective and characterized by underreporting from healthcare professionals. AIM/
objectiveTo evaluate the knowledge, attitudes and practices of PV among HCPs in Georgia.
methodsWe evaluated Georgian physicians' and nurses' knowledge, attitudes, and practices about PV in this cross-sectional study, which ran from April 2023 to June 2024. A self-administered questionnaire was distributed to 342 doctors and 342 nurses who were chosen by multistage sampling in 16 districts across six regions. The questionnaire was modified from previous research to comply with local laws. Taking into account a design effect and an expected response rate, the sample size was determined using an estimated 20% awareness level of PV procedures. Data analysis was performed using STATA version 18.0, employing chi-square tests, t-tests, and descriptive statistics.
resultsAmong participants, 76.3% encountered ADRs in their practice, but only 12.95% reported them. None of the nurses and only 10.2% of physicians used the official Ministry of Health (MOH) reporting form. The main barriers to reporting were a lack of awareness about the national reporting scheme (91.7%), uncertainty about the reporting process (76.9%), and underestimation of ADR severity (40.8%). Physicians had higher knowledge scores than nurses (mean scores: 19 vs. 16; p < 0.001), while nurses had more positive attitudes toward ADR reporting (mean scores: 6 vs. 5.6; p < 0.001).
conclusionADR reporting among Georgian HCPs is notably low due to insufficient awareness and knowledge of the PV system. This gap delays timely identification and management of adverse effects, impacting patient safety and public health. To address these challenges, strengthening PV education is essential. Integrating PV training into HCP licensing requirements, medical and nursing curricula, and Continuous Medical Education (CME) programs can enhance ADR reporting rates and engagement in drug safety monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.